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Replicative immortality is a hallmark of cancer governed by telomere maintenance. About
90% of human cancers maintain their telomeres by activating telomerase, driven by
transcriptional upregulation of telomerase reverse transcriptase (TERT). Although TERT
promoter mutations (TPMs) are a major cancer-associated genetic mechanism of TERT
upregulation, many cancers exhibit TERT upregulation without TPMs. In this study, we
described TERT Hypermethylated Oncological Region (THOR), a 433-bp genomic region
encompassing 52 CpG sites located immediately upstream of the TERT core promoter, as a
cancer-associated epigenetic mechanism of TERT upregulation. Unmethylated THOR
repressed TERT promoter activity regardless of TPMs status, and hypermethylation of
THOR counteracted this repressive function. THOR methylation analysis in 1,352 human
tumors revealed frequent (>45%) cancer-associated DNA hypermethylation in 9 of 11 (82%)
tumor types screened. Additionally, THOR hypermethylation — either independently or
along with TPMs — accounted for how approximately 90% of human cancers can aberrantly
activate telomerase. Thus, we propose THOR hypermethylation as a prevalent telomerase
activating mechanism in cancer that can act independently or in conjunction with TPMs,
further supporting the utility of THOR hypermethylation as a prognostic biomarker.
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Abstract  63 
Replicative immortality is a hallmark of cancer governed by telomere maintenance. About 90% of 64 
human cancers maintain their telomeres by activating telomerase, driven by transcriptional 65 
upregulation of telomerase reverse transcriptase (TERT). Although TERT promoter mutations 66 
(TPMs) are a major cancer-associated genetic mechanism of TERT upregulation, many cancers 67 
exhibit TERT upregulation without TPMs. In this study, we described TERT Hypermethylated 68 
Oncological Region (THOR), a 433-bp genomic region encompassing 52 CpG sites located 69 
immediately upstream of the TERT core promoter, as a cancer-associated epigenetic mechanism 70 
of TERT upregulation. Unmethylated THOR repressed TERT promoter activity regardless of 71 
TPMs status, and hypermethylation of THOR counteracted this repressive function. THOR 72 
methylation analysis in 1,352 human tumors revealed frequent (>45%) cancer-associated DNA 73 
hypermethylation in 9 of 11 (82%) tumor types screened. Additionally, THOR hypermethylation 74 
– either independently or along with TPMs – accounted for how ~90% of human cancers can 75 
aberrantly activate telomerase. Thus, we propose THOR hypermethylation as a prevalent 76 
telomerase activating mechanism in cancer that can act independently or in conjunction with 77 
TPMs, further supporting the utility of THOR hypermethylation as a prognostic biomarker. 78 
 79 
 80 
 81 
 82 
 83 
 84 
 85 
  
Introduction 86 
Replicative immortality is an attribute of cancer cells governed by telomere maintenance (1). 87 
Telomeres are repetitive nucleoprotein structures that protect chromosomal ends and shorten after 88 
each replicative cycle, playing important roles in genome stability and cancer prevention (2, 3). 89 
To achieve replicative immortality, ~90% of human cancers reactivate telomerase – a holoenzyme 90 
responsible for elongating telomeres – through re-expression of the catalytic subunit telomerase 91 
reverse transcriptase (TERT) (4). 92 
Previous studies have identified two prevalent cancer-associated TERT promoter mutations 93 
(TPMs) causing a cytidine to thymidine change at genomic loci chr5:1,295,228 (C228T) and 94 
1,295,250 (C250T) as a genetic mechanism of TERT upregulation (5-9). However, TPMs do not 95 
prevent initial bulk telomere shortening at the time of malignant transformation and only act on 96 
cells with critically short telomeres to delay replicative senescence (10), implying that TPMs alone 97 
are insufficient for cancer cells to exhibit telomerase activity required for telomere length 98 
maintenance. Moreover, common tumor types, including breast, lung, prostate, colorectal, and 99 
hematological malignancies, rarely exhibit TPMs (11-16) yet display telomerase activity, 100 
supporting the idea that other undefined TERT-upregulating mechanisms must exist.  101 
 One mechanism not yet thoroughly investigated is the epigenetic regulation of TERT. 102 
Previous seminal studies have reported an association between TERT promoter hypermethylation 103 
and elevated TERT expression in cancer (17, 18), leading to our recent work which uncovered this 104 
association in a specific region within the TERT promoter termed Upstream-of-the Transcription-105 
Start-Site (UTSS) (19). Several studies have reported frequent TERT promoter (UTSS) 106 
hypermethylation in various TERT-expressing cancer types (19-23), suggesting for an epigenetic 107 
  
mechanism of telomerase activation in multiple cancers. However, the boundaries and functional 108 
impact of this region on TERT promoter activity have not been examined in detail. 109 
In this study, we use conventional and next-generation sequencing (NGS) to uncover TERT 110 
Hypermethylated Oncological Region (THOR). Unmethylated THOR acts as a repressive element 111 
on TERT promoter activity, while methylation of THOR counteracts this repressive effect. 112 
Importantly, activating effects of TPMs on the TERT promoter is reduced when unmethylated 113 
THOR is present, implying that TPMs and THOR are two distinct TERT regulatory mechanisms. 114 
Finally, we find that THOR hypermethylation is a prevalent phenomenon in TERT-expressing 115 
tumor types regardless of their TPMs status.  116 
 117 
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 120 
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Results and Discussion 130 
Methylation landscape of the TERT promoter was examined up to ~650-bp of the transcription 131 
start site (TSS) with bisulfite-sequencing of DNA samples from normal cell lines/tissues (n=43) 132 
and TERT-expressing cancer cell lines (n=18). Using both pyrosequencing and targeted NGS 133 
technologies which produced highly consistent results (Supplemental Figure 1A–B), we defined 134 
THOR as a 433-bp genomic region within the TERT promoter (Chr5:1,295,321–1,295,753, 135 
GRCh37/hg19) that encompasses 52 CpG sites and is located upstream of common TPM sites 136 
(Figure 1A). Methylation of the CpG sites within THOR was significantly increased in cancer cell 137 
lines compared to normal samples with a mean methylation difference of 58% across THOR 138 
(P=1.49×10-9; Figure 1A and Supplemental Figure 2). Unsupervised clustering based on CpG 139 
methylation status within THOR clearly separated every TERT-expressing cancer cell line from 140 
normal samples (Figure 1B). 141 
Increased THOR methylation across all 52 CpG sites was validated and confirmed in 142 
tumors from various tissues (n=87; Figure 2A), and unsupervised clustering separated 82% (71/87) 143 
of these tumors from normal samples (Figure 2B). To examine the extent of THOR methylation 144 
in larger tumor cohorts, we tested and confirmed that 5 CpG sites (UTSS) (19) within THOR 145 
accurately represent average THOR methylation (Supplemental Figure 3). Using these CpG sites, 146 
we screened 1,352 tumor and 80 normal samples from various tissues to assess THOR methylation 147 
in cancer. The median THOR methylation of normal samples was 7.0% with no samples exceeding 148 
18.3%, while most adult cancer types exhibited significantly higher median THOR methylation 149 
(P<0.05) with 91.4% of all tumors exceeding the median THOR methylation level of normal 150 
tissues. Of note, low THOR methylation observed in thyroid cancers may be associated with their 151 
known lower malignant potential and better prognosis compared to other tumor types. Other 152 
  
tumors exhibiting low and heterogeneous methylation levels such as skin and bone cancers utilize 153 
other mechanisms for telomere maintenance, such as TPMs and Alternative Lengthening of 154 
Telomeres (ALT) pathway respectively (24). Furthermore, we compared patient-matched normal-155 
tumor samples in a subset of lung (n=32) and prostate (n=67) cancers, in which 89.9% (89/99) of 156 
tumours exhibited higher THOR methylation compared to matched normal tissue by a median of 157 
13.9% (Figure 2D), corroborating THOR methylation as a cancer-associated epigenetic event.  158 
Prevalence of THOR methylation in cancer was assessed by dichotomizing tumor samples 159 
as hypomethylated or hypermethylated using a cut-off value of 16.1%, by adding 2 standard 160 
deviations to the mean methylation of normal samples as previously described (see methods) (19, 161 
20). All cancer types screened exhibited high prevalence (>45%) of THOR hypermethylation 162 
except thyroid cancers (3%) and melanomas (30%; Figure 2E). Interestingly, tumors in which 163 
TPMs are rarely observed (i.e. prostate, breast, blood, and colon cancers) (11, 12, 15, 16) displayed 164 
higher prevalence of THOR hypermethylation compared to those in which TPMs are commonly 165 
found (i.e. skin, bladder, and brain cancers) (5, 8, 25) (Figure 2E), suggesting that THOR 166 
hypermethylation may be a crucial TERT-activating mechanism in tumors without TPMs. 167 
Together, these observations highlight a potential cancer-associated mechanism of telomerase 168 
activation through THOR hypermethylation and suggest the usefulness of THOR 169 
hypermethylation signature in differentiating normal and cancerous tissue. 170 
To examine the role of THOR as a transcriptional regulatory element of TERT, we first 171 
performed 5’ truncation analysis of the TERT promoter using reporter gene constructs spanning 172 
both the TPM sites and THOR. A continual increase in reporter gene expression was observed in 173 
a cancer cell line (LN229) as THOR was gradually truncated from the 5’ end, with the pTERT-174 
214 construct displaying peak promoter strength (Figure 3A). Further truncation of 82-bp (pTERT-175 
  
132) resulted in a ~2-fold reduction of reporter gene expression, indicating that the minimal TERT 176 
core promoter is a region up to 214-bp upstream of the TERT TSS, encompassing the TPM sites 177 
and proximal 75-bp of THOR. Importantly, addition of rTHOR to the TERT core promoter resulted 178 
in a significant decrease in reporter gene expression compared to the TERT core promoter alone in 179 
LN229 (Figure 3A) and multiple cancer cell lines from different tissues (Supplemental Figure 4). 180 
This region – which we defined as repressive THOR (rTHOR, Chr5:1,295,395–1,295,743) – is a 181 
functional region within THOR that represses TERT expression when unmethylated. We then 182 
tested the effect of rTHOR re-methylation using a unique reporter gene plasmid completely devoid 183 
of CpG sites (pCpGfree-promoter-Lucia, Invivogen). rTHOR was cloned upstream of the modified 184 
CpG-free hEF1 promoter (pCpG(+rTHOR)) and was efficiently methylated in vitro 185 
(pCpG(+rTHORMeth); Supplemental Figure 5). Hypermethylation of rTHOR resulted in a 186 
significant increase in reporter gene expression in LN229 and two additional cancer cell lines 187 
(HeLa and HT1080) (Figure 3B), implying that methylation of THOR counteracts the repressive 188 
effect of rTHOR. Finally, we treated brain cancer and glioma stem cell lines which harbor THOR 189 
hypermethylation and high TERT expression with the demethylation agent Decitabine, which 190 
resulted in reduced THOR methylation and TERT expression (Supplemental Figure 6). In contrast, 191 
TERT expression was not altered in normal embryonic stem cells lacking THOR hypermethylation 192 
(Supplemental Figure 6). These observations infer that cancer cells hypermethylate THOR to 193 
counteract the repressive effect of rTHOR and promote TERT upregulation. 194 
High prevalence of THOR hypermethylation in tumor types that commonly harbor TPMs 195 
(Figure 2E) and the previous finding that TPMs alone are insufficient in preventing initial bulk 196 
telomere shortening at the time of malignant transformation (10) led us to investigate the 197 
relationship between THOR and TPMs. In contrast to the cancer-associated hypermethylation 198 
  
observed within THOR, the average DNA methylation of the CpG sites at the TPM locus 199 
(Chr5:1,295,225 – 1,295,263, GRCh37/hg19) was ubiquitously low (<10%) in normal tissue 200 
(0.8%), tumor samples (4.4%) and TERT-expressing cancer cell lines (9.2%; Figure 1A and 2A). 201 
This suggests that the genomic loci encompassing either THOR or TPMs are distinct TERT 202 
regulatory regions. To functionally investigate the repressive effect of unmethylated rTHOR in the 203 
context of TPM, we compared reporter gene expression in four constructs: pTERT(+rTHOR) and 204 
pTERT(−rTHOR), which contain the TERT core promoter with and without rTHOR respectively, 205 
and in the presence and absence of C228T TPM (Figure 4A). As expected, the addition of rTHOR 206 
to the TERT core promoter decreased promoter strength by an average ~5-fold in all 3 cancer cell 207 
lines tested, while C228T mutation resulted in an average ~5-fold increase (Figure 4A). The 208 
addition of rTHOR to the C228T mutated TERT core promoter effectively counteracted the 209 
activating effect of this mutation and the activity was comparable to that of the wild-type TERT 210 
promoter without rTHOR. These findings indicate that THOR and TPMs are non-redundant but 211 
discrete regulatory mechanisms of TERT expression in cancer.  212 
To explore the impact of these mechanisms on telomerase activation in cancer, we first 213 
examined whether they can co-exist in 10 TERT-expressing cancer cell lines. All cell lines 214 
exhibited THOR hypermethylation and, importantly, five showed co-existence of the two TERT 215 
activating mechanisms (Figure 4B). However, there was no significant difference observed in the 216 
level of TERT expression between cancer cell lines when TPMs were present or absent 217 
(Supplemental Figure 7). This suggests that in certain cancers where TPM is absent, other 218 
mechanisms such as THOR hypermethylation contribute to TERT expression.  Second, we 219 
assessed the prevalence and co-existence of these mechanisms in cancer types in which TPMs are 220 
either frequently or rarely present (Figure 4C). In a cohort of cancers that commonly exhibit TPMs 221 
  
(glioma/melanoma, n=396), we frequently (43%) observed TPMs and THOR hypermethylation 222 
together while 45% of the tumors exhibited only one of the mechanisms. Meanwhile, in a cohort 223 
of cancers that lack TPMs (prostate, lung, breast, and colon cancers, n=78), 90% of the tumors 224 
exhibited only THOR hypermethylation. Nonetheless, in both groups, the prevalence of THOR 225 
methylation together with TPMs reflected the overall frequency of telomerase-dependent tumors 226 
(~90%). Third, we screened a subset of gliomas – tumors that exhibit heterogeneous telomere 227 
maintenance mechanisms including THOR hypermethylation, TPMs, and ALT (n=21; Figure 4D). 228 
Interestingly, 93.3% (14/15) of TERT-expressing gliomas displayed THOR hypermethylation 229 
alone or with TPMs, while 83.3% (5/6) of gliomas that lacked TERT expression were missing 230 
either TERT-activating mechanism but were primarily dependent on ALT for telomere 231 
maintenance. These observations highlight the role of THOR hypermethylation as one of TERT-232 
upregulatory mechanisms in cancer, either independently or in conjunction with TPMs. 233 
Although we describe THOR hypermethylation as an additional TERT-upregulatory 234 
mechanism, understanding its biological mechanism needs further investigation. A recent study 235 
has associated allele-specific hypomethylation and active histone marks (H3K4me2/3) in cancer 236 
cell lines that harbor TPM (26). In this case, THOR hypermethylation may act as a regulatory 237 
mechanism strictly through transcription factor binding, enabling TERT expression even in the 238 
allele without active histone marks. Cis-acting transcriptional repressors such as WT1 and MZF-239 
2 are known to bind the genomic region within THOR (27), but whether or not their binding is 240 
methylation-sensitive requires further investigation. Another interesting aspect of THOR 241 
hypermethylation is that it may regulate other genes in the proximity of TERT which ultimately 242 
affect TERT expression, such as hTERT antisense promoter associated (hTAPAS) non-coding RNA 243 
whose promoter overlaps with the TERT promoter (28). Lastly, to explore the co-existence and 244 
  
interplay between THOR hypermethylation and TPMs in more detail, single-cell level analyses 245 
should be performed in the future. 246 
In summary, this study defined THOR as a region of cancer-associated DNA 247 
hypermethylation, located adjacent to the TERT core promoter and common TPM sites. We 248 
demonstrated that unmethylated rTHOR is a repressive element of the TERT promoter and 249 
hypermethylation counteracts this effect, suggesting that cancer cells methylate THOR to 250 
upregulate TERT expression and activate telomerase. In addition, our study proposes two clinically 251 
relevant implications. First, unraveling the exact mechanism of THOR hypermethylation-driven 252 
TERT expression will uncover potential therapeutic targets for cancer treatment. Second, together 253 
with TPMs, the discovery of this TERT-upregulating mechanism in cancer accounts for how ~90% 254 
of human cancers activate telomerase. Our findings provide biological insight as to why tumors 255 
with THOR hypermethylation are associated with poorer clinical outcome (19, 20, 22, 23), further 256 
highlighting its value as a potential prognostic biomarker. 257 
 258 
Materials and Methods 259 
A complete description of the methods and statistical analysis is provided in the Supplementary 260 
Materials. Unsupervised clustering heatmap was created with modified version of Methylation 261 
plotter (29). NGS Data is available on GEO public Database [Accession#: GSE120511]. 262 
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Figures 376 
 377 
Figure 1. Defining THOR through DNA CpG methylation analysis of the TERT promoter. 378 
(A) Average CpG methylation of the TERT promoter in normal cell lines/tissues (n=43, blue) and 379 
TERT-expressing cancer cell lines (n=18, red). THOR (TERT Hypermethylated Oncological 380 
Region) is a 433-bp region (-140 to -572, relative to TSS) comprising of 52 CpG sites and located 381 
adjacently upstream of the common C228T and C250T TPMs (purple triangles). UTSS 382 
encompasses 5 CpG sites within THOR. ATG and TSS are start codon and transcription start site 383 
of the TERT promoter, respectively. Lollipops represent individual CpG sites. (B) Methylation 384 
heatmap generated from unsupervised clustering displays methylation percentage of each CpG site 385 
  
within THOR for normal cell lines/tissues (n=43, blue) and TERT-expressing cancer cell lines 386 
(n=18, red). Grey color indicates unavailability of data. 387 
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Figure 2. THOR hypermethylation is prevalent in human cancers. (A) Average DNA CpG 410 
methylation of the TERT promoter in normal cell lines/tissues (n=43, blue) and tumor samples 411 
(n=87, red). (B) Methylation heatmap generated from unsupervised clustering displays 412 
methylation percentage of each CpG site within THOR for normal cell lines/tissues (n=43) and 413 
tumor samples (n=87). Grey color indicates unavailability of data. (C) Box-and-whisker plot 414 
shows the median and distribution of the average THOR methylation levels in normal samples 415 
(n=80, blue) and samples from various tumor tissue types (n=1,352, red; Sidak’s multiple 416 
comparisons test, *P<0.05). (D) Difference in average THOR methylation level between each 417 
paired normal-tumor samples (n=99, left plot) and distribution of differences in THOR methylation 418 
  
(right plot, median&IQR; Paired t-test, ****P<0.0001). (E) Pie charts display the frequencies of 419 
THOR hypermethylation signature across various tumor types. 420 
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Figure 3. Hypermethylation counteracts the repressive effect of rTHOR on TERT promoter 443 
activity. For the data shown, each experiment was performed in triplicates. (A) Schematic 444 
representation of the TERT promoter is shown. Repressive THOR (rTHOR, red) is a transcriptional 445 
regulatory element within THOR, upstream of the TERT core promoter (blue). Normalized fold 446 
changes in TERT promoter activity are shown for the specified luciferase constructs transfected 447 
into glioblastoma cell line LN229. The numbers in the plasmid constructs indicate the distance 448 
(bp) from TERT TSS. (Unpaired t-test, *P<0.05). (B) Normalized fold changes in hEF1 promoter 449 
activity are shown for CpG-free constructs when rTHOR is unmethylated or methylated (in-vitro) 450 
in cancer cell lines LN229, HeLa, and HT1080 (Unpaired t-test, *P<0.05). 451 
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Figure 4. Co-existence and interplay of TPM and THOR hypermethylation in human 456 
cancers. For the data shown, each experiment was performed in triplicates. (A) Normalized fold 457 
changes in TERT promoter activity are shown for the specified luciferase constructs, with presence 458 
and absence of THOR and/or C228T TPM, in glioblastoma cell line LN229 and medulloblastoma 459 
cell lines ONS76 and UW228 (Unpaired t-test, *P<0.05, **P<0.01, ***P<0.001). (B) TERT 460 
expression (mean±SD, black bars/dots, left Y-axis) and average THOR methylation level (red dots, 461 
right Y-axis) are shown in human primary (1°) and cancer cell lines. TERT regulation-associated 462 
  
characteristics for all cell lines are shown below the graph. (C) Pie charts display the frequencies 463 
of TPMs and THOR hypermethylation signature in TPM-common tumors (glioma/melanoma) and 464 
TPM-independent tumors (prostate/lung/colon/breast cancers). (D) TERT expression (mean±SD, 465 
black bars/dots, left Y-axis) and THOR methylation level (red dots, right Y-axis) are shown in a 466 
subset of adult gliomas (n=21). TERT regulation-associated characteristics for these samples are 467 
shown below the graph. 468 
